Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth A Karron

Showing results (1-10 of 153) with videos related to

Pageof 16
Sort By:
The New England Journal of Medicine|April 5, 2023
RSV Illness in the Young and the Old - The Beginning of the End?Ruth A Karron
The New England Journal of Medicine|September 13, 2023
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. ReplyRuth A Karron
Science (New York, N.Y.)|May 14, 2021
Preventing respiratory syncytial virus (RSV) disease in childrenRuth A Karron
The Pediatric Infectious Disease Journal|January 20, 2004
The future of respiratory syncytial virus vaccine developmentFernando P Polack, Ruth A Karron
Lancet (London, England)|July 11, 2017
Determining the burden of respiratory syncytial virus disease: the known and the unknownRuth A Karron, Robert E Black
Science (New York, N.Y.)|February 11, 2012
Public health and biosecurity. The obligation to prevent the next dual-use controversyRuth R Faden, Ruth A Karron
The Lancet. Infectious Diseases|December 22, 2016
Vaccination against respiratory syncytial virus in pregnancyJessica E Atwell, Ruth A Karron
The Lancet. Respiratory Medicine|September 4, 2017
Determining the outcomes of interventions to prevent respiratory syncytial virus disease in children: what to measure?Ruth A Karron, Heather J Zar
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2003
Progress in the development of respiratory syncytial virus and parainfluenza virus vaccinesAnna P Durbin, Ruth A Karron
JAMA|April 30, 2021
Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S VaccineRuth A Karron, Nigel S Key, Joshua M Sharfstein
Pageof 16

Showing results (1-10 of 153) with videos related to

Sort By:
Pageof 16
The New England Journal of Medicine|April 5, 2023
RSV Illness in the Young and the Old - The Beginning of the End?Ruth A Karron
The New England Journal of Medicine|September 13, 2023
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. ReplyRuth A Karron
Science (New York, N.Y.)|May 14, 2021
Preventing respiratory syncytial virus (RSV) disease in childrenRuth A Karron
The Pediatric Infectious Disease Journal|January 20, 2004
The future of respiratory syncytial virus vaccine developmentFernando P Polack, Ruth A Karron
Lancet (London, England)|July 11, 2017
Determining the burden of respiratory syncytial virus disease: the known and the unknownRuth A Karron, Robert E Black
Science (New York, N.Y.)|February 11, 2012
Public health and biosecurity. The obligation to prevent the next dual-use controversyRuth R Faden, Ruth A Karron
The Lancet. Infectious Diseases|December 22, 2016
Vaccination against respiratory syncytial virus in pregnancyJessica E Atwell, Ruth A Karron
The Lancet. Respiratory Medicine|September 4, 2017
Determining the outcomes of interventions to prevent respiratory syncytial virus disease in children: what to measure?Ruth A Karron, Heather J Zar
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2003
Progress in the development of respiratory syncytial virus and parainfluenza virus vaccinesAnna P Durbin, Ruth A Karron
JAMA|April 30, 2021
Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S VaccineRuth A Karron, Nigel S Key, Joshua M Sharfstein
Pageof 16